The Cholangitis drugs in development market research report provides comprehensive information on the therapeutics under development for Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cholangitis. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Cholangitis - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cholangitis and features dormant and discontinued products.

GlobalData tracks 45 drugs in development for Cholangitis by 36 companies/universities/institutes. The top development phase for Cholangitis is preclinical with 21 drugs in that stage. The Cholangitis pipeline has 43 drugs in development by companies and two by universities/ institutes. Some of the companies in the Cholangitis pipeline products market are: Pliant Therapeutics, Mirum Pharmaceuticals and AbbVie.

The key targets in the Cholangitis pipeline products market include Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV), Integrin Beta 6 (ITGB6), and Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2).

The key mechanisms of action in the Cholangitis pipeline product include Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Antagonist with five drugs in Phase II. The Cholangitis pipeline products include eight routes of administration with the top ROA being Oral and ten key molecule types in the Cholangitis pipeline products market including Small Molecule, and Peptide.

Cholangitis overview

Cholangitis refers to inflammation of the bile ducts, which are tubes that carry bile from the liver to the gallbladder and small intestine. This condition can be acute or chronic and is often caused by a bacterial infection or blockage of the bile ducts. Cholangitis can cause a range of symptoms, which may include abdominal pain, particularly in the upper right side; jaundice (yellowing of the skin and eyes); fever and chills; nausea, vomiting, and loss of appetite; dark urine and pale stools; and generalized weakness or fatigue.

For a complete picture of Cholangitis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.